Nightstar Therapeutics (formerly known as NightstaRx) is a clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The Company’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy.
|New Enterprise Associates, Wellington Management, Redmile Group, Syncona Partners LLP., Syncona Partners LLP|
|USD||H1, 2016||H1, 2017|
Depreciation and Amortization
Cash From Operating Activities
Nightstar Therapeutics has 163 Twitter Followers. The number of followers has decreased 0.6% month over month and increased 0.1% quarter over quarter
When was Nightstar Therapeutics founded?
Nightstar Therapeutics was founded in 2013.
Who are Nightstar Therapeutics key executives?
Nightstar Therapeutics's key executives are David Fellows, Tuyen Ong and Gregory Robinson.
How many employees does Nightstar Therapeutics have?
Nightstar Therapeutics has 47 employees.
Who are Nightstar Therapeutics competitors?
Competitors of Nightstar Therapeutics include LogicBio Therapeutics, BioSavita and OYAGEN.
Where is Nightstar Therapeutics headquarters?
Nightstar Therapeutics headquarters is located at 215 Euston Rd, London.
Where are Nightstar Therapeutics offices?
Nightstar Therapeutics has offices in London and Lexington.
How many offices does Nightstar Therapeutics have?
Nightstar Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies